- Home
- UCL vs MREO Comparison
UCL vs MREO Comparison
Compare UCL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCL | MREO |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 52.5M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | UCL | MREO |
|---|---|---|
| Price | $1.40 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 5.4K | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $11.60 | $6,000.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.20 |
| 52 Week High | $4.19 | $2.94 |
Technical Indicators
Market Signals| Indicator | UCL | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 36.42 |
| Support Level | $1.23 | $0.32 |
| Resistance Level | $1.67 | $0.42 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 45.90 | 15.80 |
Price Performance
Historical ComparisonAbout UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).